arrow
F

Francesco Orlando

university of trento
H指数:12
被引数:637

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

联合ctDNA和血清PSA动态监测转移性前列腺癌开始一线治疗: 一项前瞻性国家队列研究

2026-05-150
OAAI
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer. the STAMPEDE Phase 3 Randomized Clinical Trial

血浆AR改变及强化激素治疗前列腺癌的时机:STAMPEDE III期随机临床试验

2025-02-270
PRE
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

进展性前列腺癌患者开始使用多西他赛联合或不联合恩扎卢替尼时的液体活检:PRESIDE 3b期试验的生物标志物研究

2025-02-011
OAAI
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation
2023-12-1814
OAAI
Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
2023-10-010
OA
Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
2023-10-010
PRE
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
2022-05-279
OAAI
Favorable Outcomes of Liver Transplantation from Controlled Circulatory Death Donors Using Normothermic Regional Perfusion Compared to Brain Death Donors
2020-06-2970
OAAI
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
2020-02-24135
OA